REVBW — REVELATION BIOSCIENCES, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1810560 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -3,383,576 -3,315,513 10,022,097 9,121,630 2,788,395
Jun 2026 0 — -3,662,241 -3,323,384 12,497,932 11,482,792 2,430,946
Mar 2026 0 — -3,092,500 -3,009,051 15,044,282 14,113,415 2,055,329
Dec 2025 0 — -2,571,588 -2,511,006 11,582,924 10,700,331 2,721,929

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-9,327,937
Investing CF
$-111,507
Financing CF
$15,748,365
CapEx
$-111,507
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-55,751,722
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-11,269,340
Pretax Income TTM
$-10,750,617
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -9,070,814 -8,913,649 11,582,924 2,721,929 8,860,995 -8,269,581
Dec 2024 0 -7,975,109 -15,038,536 6,622,049 1,913,667 4,708,382 -18,321,276
Dec 2023 0 -8,656,664 -120,254 12,212,609 5,564,894 6,647,715 -7,286,286
Dec 2022 0 -10,864,511 -10,829,549 5,503,415 4,450,962 1,052,453 -11,219,396
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-10,750,617
OpCashFlow TTM
—
Assets (Latest)
$12,497,932
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $1.26T $1415.55 —
JNJ JOHNSON & JOHNSON $670.92B $278.70 —
ABBV AbbVie Inc. $517.59B $292.82 —
MRK Merck & Co., Inc. $353.44B $143.37 —
NVS NOVARTIS AG $302.46B $159.13 —

News headlines (Yahoo Finance, 1h cache)

Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives
2026-11-16 14:00 · Yahoo
REVB Makes Major Announcement
2026-11-16 13:18 · Yahoo
REVB Approaching Important Period in Great Shape
2026-11-06 11:00 · Yahoo
Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026
2026-11-05 22:29 · Yahoo
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
2026-10-16 13:00 · Yahoo
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
2026-08-19 13:00 · Yahoo
REVB Approaching a Critical Inflection Point
2026-08-07 12:14 · Yahoo
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
2026-08-06 20:15 · Yahoo
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
2026-08-03 13:00 · Yahoo
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-21 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.